Vaishali Shukla
Vice President, CGT & API Global Expansion Eli Lilly & Co.
Vaishali Shukla, PhD, is Vice President of Cell & Gene Therapy and API Global Expansion at Eli Lilly and Company, where she leads global efforts to scale advanced therapy manufacturing and supply networks. With more than 20 years of experience in the biopharmaceutical industry, she has worked across areas including early clinical development through commercialization of cell and gene therapies, biologics, peptides, ADCs, and small molecules. In her current role, Vaishali oversees strategy for API and CGT manufacturing expansion and plays a key role in enabling the global delivery of advanced therapies with quality and consistency.
Seminars
Tuesday 15th September 2026
Panel Discussion: Weighing the Pros & Cons of Automated Manufacturing
9:30 am
- Exploring the adoption of automated manufacturing process to enhance consistency, output and decrease variability
- Examining integration and flexibility challenges in automation to inform realistic implementation strategies
- Analyzing the impact of automation on cost of goods to optimize resource allocation and support sustainable clinical and commercial manufacturing
Thursday 17th September 2026
Panel Discussion: Accelerating Veinto-Vein Time through Innovative QC Testing Strategies
2:35 pm
- Exploring rapid sterility testing methods, including ATP release assays and NGS-based microbial detection, to reduce traditional 7-day timelines
- Implementing rapid QC testing to accelerate vein-to-vein time without compromising safety and regulatory compliance
- Highlighting emerging technologies demonstrating rapid, reliable testing to support clinical and commercial qc workflows
